Feasibility of Fluciclovine PET/CT to Identify Brain Metastasis Read more about Feasibility of Fluciclovine PET/CT to Identify Brain Metastasis
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke Read more about A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke
A Phase Ill, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration Of Comp360 in Participants With Treatment- Read more about A Phase Ill, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of a Single Administration Of Comp360 in Participants With Treatment-
A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus In Read more about A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus In
A Phase 2b, Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder (TPIP) Read more about A Phase 2b, Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Treprostinil Palmitil Inhalation Powder (TPIP)
A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis Eff Read more about A Phase 2b Multicenter, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderately to Severely Active Ulcerative Colitis Eff
A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre Read more about A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors Read more about A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP) Read more about Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP)
Integrative Medicine in Hematology Oncology Fellowship Read more about Integrative Medicine in Hematology Oncology Fellowship
